We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Store » Books » Cut Drug Approval Time with a 505(b)(2)

Other Options

PDF Edition

$397.00

PDF Edition - 3-4 Copies (10% Off)

$357.00

PDF Edition - 5-6 Copies (15% Off)

$337.00

PDF Edition - 7-9 Copies (20% Off)

$317.00

PDF Edition - 10+ Copies (25% Off)

$297.00

Cut Drug Approval Time with a 505(b)(2)

$397.00
Also Available:
Regulatory Affairs

Product Details

Cut Drug Approval Time
with a 505(b)(2)

Unsure of how to use the 505(b)(2) process?

Here's an opportunity to get all the details in a new report available from FDAnews.

A 505(b)(2) can provide relatively fast-track approval for a wide range of products, especially for those that represent a limited change from an existing or approved drug. Ideal candidates include:

  • New chemical entities (NCEs)/new molecular entities (NMEs)
  • Changes to previously approved drugs
     

  • Changes in dosage form, strength or route of administration
     

  • Changes from prescription (Rx) indications to over-the-counter (OTC) indications
     

  • Substitution of an active ingredient in a combination product
     

Of course, the devil is in the details — and that's why this report with valuable tips from Kurt Karst, Director with Hyman, Phelps & McNamara,and a widely respected legal authority and blogger on 505(b)(2) issues — is a must have.  Readers will learn:

  • How the 505(b)(2) is similar to and differs from the 505(b)(1) standard NDA and the 505(j) ANDA
  • How drugs approved under the 505(b)(2) process can obtain either three or five years of patent exclusivity
  • When applications involving changes to approved drugs can use the 505(b)(2) pathway
  • How to choose a listed drug for a 505(b)(2) application
  • About FDA interpretations of the law affecting 505(b)(2) applications
  • About fees and restrictions involved in using the 505(b)(2) process
  • And more

Order Your Copy Today

PDF Edition — $397

 

Available Format

PDF Edition — $397

Table of Contents

  • Ways to Use the 505(b)(2)
  • 505(b)(2) Patent and Exclusivity Protections
  • FDA Interpretations
  • Recent Challenges Concerning 505(b)(2)s

View the entire TOC

Multi-user Access

Save money with a license agreement allowing significant numbers of users access to an electronic version of this book. For multi-user access to multiple titles, FDAnews offers the FDAnews Online Library — a personalized collection of FDAnews publications that is fully searchable. Contact Customer Service for a quote or more information.

Our Guarantee

Not satisfied with your publication? For the PDF version, you must notify FDAnews within 24 hours of receipt of purchase and we will refund 100 percent of your purchase price.

  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing